Compare WMK & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WMK | NRIX |
|---|---|---|
| Founded | 1912 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | N/A | 2020 |
| Metric | WMK | NRIX |
|---|---|---|
| Price | $66.81 | $19.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $26.08 |
| AVG Volume (30 Days) | 111.9K | ★ 1.8M |
| Earning Date | 11-04-2025 | 01-27-2026 |
| Dividend Yield | ★ 2.05% | N/A |
| EPS Growth | ★ 6.99 | N/A |
| EPS | ★ 3.81 | N/A |
| Revenue | ★ $4,894,832,000.00 | $83,687,000.00 |
| Revenue This Year | N/A | $58.38 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.17 | ★ N/A |
| Revenue Growth | 2.20 | ★ 48.32 |
| 52 Week Low | $61.53 | $8.18 |
| 52 Week High | $90.23 | $22.95 |
| Indicator | WMK | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 52.66 | 70.09 |
| Support Level | $64.54 | $16.02 |
| Resistance Level | $68.00 | $22.50 |
| Average True Range (ATR) | 1.70 | 1.33 |
| MACD | 0.21 | 0.32 |
| Stochastic Oscillator | 67.89 | 72.19 |
Weis Markets Inc is a U.S.-based company that is principally engaged in retailing food products in Pennsylvania and surrounding states. The company's products mainly belong to the following categories: center-store goods, fresh goods, pharmacy services, fuel, and others. The center-store goods include groceries, dairy products, frozen foods, alcoholic beverages, and general merchandise items. The fresh goods include meats, seafood, floral, prepared foods, and bakery products. The center-store goods and fresh goods jointly account for the majority of the company's total revenue.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.